Videos / New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3
In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Cow’s Milk Allergy in Infants and Children

Arexvy is on the NIP – What You Need to Know

Eczema Practical Updates for General Practice

Inhaler Devices Workshop

expert
Public Health Physician and Infectious Diseases Epidemiologist; Professor, School of Medicine, Griffith University, Queensland